Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

4.360 +0.050 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 5 6 7 8 9 Next >
Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Via ACCESSWIRE
Evotec Announces Change in Management Board
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024. 
Via Benzinga
Comment on Withdrawn Non-Binding Offer
Via ACCESSWIRE
Insights into Evotec's Upcoming Earnings
Via Benzinga
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Via ACCESSWIRE
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
Via ACCESSWIRE
Intuit Issues Weak Forecast, Joins Reddit And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio. 
Via Benzinga
Comment on Media Report
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
Via ACCESSWIRE
Evotec Announces Change in Management Board
Via ACCESSWIRE
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company. 
Via Benzinga
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
Via ACCESSWIRE
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday
Via Benzinga
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Is Evotec Stock Gaining Today?
Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment. 
Via Benzinga
Sherwin-Williams, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. 
Via Benzinga
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Via ACCESSWIRE
FedEx Reports Downbeat Results, Joins MillerKnoll And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
From X-Chem
Via Business Wire
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
Exposures Layoff
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.